



Art/ 1617  
Lfw

CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 26, 2004  
Date

  
Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe Sophia Ran and  
Rolf A. Brekken (As Amended)

Serial No.: 09/351,149

Filed: July 12, 1999

For: CANCER TREATMENT KITS COMPRISING  
THERAPEUTIC CONJUGATES THAT BIND  
TO AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 3999.002383

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22131-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Final Official Action has been received in the present application. However, this Supplemental Information Disclosure Statement is being submitted in an abundance of caution and should be enterable under 37 C.F.R. § 1.97(d) in light of the following information. In the alternative, for completeness and to most fully comply with the duty of disclosure, the enclosed document should be placed in the file in accordance with 37 C.F.R. § 1.97(i).

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in this PTO-1449 were not cited in a communication from a foreign patent office in a foreign counterpart to the present application. The listed documents were provided by European legal representatives of another party in connection with their defense to an Opposition filed against their European patent by the licensee of the present application. Receipt of the listed documents began on about August 23, 2004, and was completed on about August 27, 2004, and the present statement is being filed within three months of the first receipt of the listed documents.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.97(d) and 1.17(p) be due, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002383.

Respectfully submitted,  
Williams, Morgan & Amerson, P.C.  
Customer No. 23720



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

10333 Richmond, Suite 1100  
Houston, Texas, 77042  
(713) 934-4079

Date: October 26, 2004

Form PTO-1449 (modified)

Atty. Docket No.

3999.002383

Serial No.

09/351,149

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Thorpe, Ran and Brekken

Filing Date:

July 12, 1999

Group:

1617

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C131	Ben-Hur and Orenstein, "The Endothelium and Red Blood Cell as Potential Targets in PDT-Induced Vascular Stasis," <i>J. Radiat. Biol.</i> , 60(1/2):293-301, 1991.
	C132	Folkman, "Tumor Angiogenesis," <i>Adv. Cancer Res.</i> , 43:175-203, 1985.
	C133	Gschwind <i>et al.</i> , "The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy," <i>Nature Reviews/Cancer</i> , 4:361-370, 2004.
	C134	Martiny-Baron and Marm�, "VEGF-Mediated Tumour Angiogenesis: A New Target for Cancer Therapy," <i>Curr. Opin. Biotech.</i> , 6:675-680, 1995.
	C135	McDonald and Baluk, "Significance of Blood Vessel Leakiness in Cancer," <i>Cancer Research</i> , 62:5381-5385, 2002.
	C136	Murata <i>et al.</i> , "Immunohistochemical Detection of Extravasated Fibrinogen (Fibrin) in Human Diabetic Retina," <i>Graefe's Arch. Clin. Exp. Ophthalmol.</i> , 230:428-431, 1992.
	C137	Risau, "What, if anything, is an Angiogenic Factor?" <i>Cancer Metastasis Rev.</i> , 15:149-151, 1996.
	C138	Wiig <i>et al.</i> , "Interstitial Fluid Pressure in DMBA-Induced Rat Mammary Tumours," <i>Scand. J. Clin. Lab. Invest.</i> , 42:159-164, 1982.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.